Co-organized with Life Science Sweden, this webinar will focus on the key considerations for transitioning small molecules from preclinical through clinical development. Experts will discuss the technological aspects of drug development and describe practical approaches to improve bioavailability of poorly soluble drugs. Register here
In addition, the speakers will discuss the ways physiologically based pharmacokinetic (PBPK) models are used to predict the pharmacokinetics (PK) of drugs to support drug design study. Recent advances in vivo and ex vivo models used in preclinical studies of drug development will also be discussed.
Early Drug Development Considerations: Strategies and Practice
Stephen Tindal, Director, Science & Technology, Catalent
Integrating In Silico, In Vitro and In Vivo Data with PBPK Modeling for Improved Formulation Development
Jan Neelissen, Scientific Advisor, Science & Technology, Catalent
The Importance of Clinically-Relevant Preclinical Models in Drug Development
Anna Grabowska, Professor of Cancer Microenvironment, University of Nottingham